Description
Venlafaxine is an inhibitor of the serotonin transporter (SERT), norepinephrine transporter (NET), and monoamine oxidase (MAO). Venlafaxine exhibits antidepressant, analgesic, and neuroprotective activities. Venlafaxine decreases pain in animal models of diabetic neuropathy and improves cognitive performance and decreases oxidative stress parameters in 3-NP-treated animal models of Huntington’s disease.
References
Vidal R, Diaz A, Pazos A, et al. Region-specific regulation of 5-HT1B receptors in the rat brain by chronic venlafaxine treatment. Psychopharmacology (Berl). 2013 Sep;229(1):177-85. PMID: 23609771.
Cegielska-Perun K, Bujalska-Zadrożny M, Tatarkiewicz J, et al. Venlafaxine and neuropathic pain. Pharmacology. 2013;91(1-2):69-76. PMID: 23183148.
Fisar Z, Hroudová J, Raboch J. Inhibition of monoamine oxidase activity by antidepressants and mood stabilizers. Neuro Endocrinol Lett. 2010;31(5):645-56. PMID: 21200377.
Kumar P, Kalonia H, Kumar A. Nitric oxide mechanism in the protective effect of antidepressants against 3-nitropropionic acid-induced cognitive deficit, glutathione and mitochondrial alterations in animal model of Huntington's disease. Behav Pharmacol. 2010 May;21(3):217-30. PMID: 20480544.